News for Healthier Living

Heart and Kidney Outcomes After Canagliflozin Treatment in Older Adults

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients' age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 - 27.

October 25, 2024


October 31 2024

October 30 2024

October 29 2024

October 28 2024

October 27 2024

October 26 2024

October 25 2024

October 24 2024

October 23 2024

October 22 2024

October 21 2024

October 20 2024

October 19 2024

October 18 2024

October 17 2024